Bausch Health has launched a shareholder rights plan—also known as a poison pill defense—designed to prevent any one entity ...

After enacting a “poison pill” defense to protect itself from unwanted potential buyers, Bausch Health has spotted a major ...

European fintech Pliant has reportedly acquired the Austrian Insurtech hi.health. The acquisition enables Pliant to apply its payment expertise to the insurance sector while “gaining industry ...

Boaz Weinstein, Founder and Chief Investment Officer of Saba, commented: “By readopting a poison pill that was already deemed unlawful, ASA, Chair Mary Joan Hoene and Director William Donovan ...

PLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. SOUTH SAN ...

Bausch Health, which has engaged financial advisors to help finance its large debt, last week adopted a shareholders' rights plan, or a "poison pill", to prevent investors from acquiring a more ...

Forget injections. A new drug promises to be just as effective as Ozempic — but is taken as a daily pill. Called orforglipron, the results of a new clinical trial announced Thursday by ...

Now, a new contender is stepping into the spotlight. It’s called Orforglipron, and it’s a daily weight loss pill that could be a game-changer in how we manage both weight and blood sugar.

A daily pill appears to lower blood sugar in people with type 2 diabetes as effectively as injectable drugs like Ozempic and Mounjaro. The medication, called orforglipron, also led to substantial ...

Bausch, which last week adopted a poison-pill plan to prevent any unsolicited takeover bid, said Tuesday it has learned Icahn and affiliates have amassed an economic interest covering about 34% of ...

The trend is especially worrisome due to the corresponding rise of calls to poison control centers, especially among US adults 30 and older, according to the research. “As these drugs are used ...